Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450dbl phenotypes in malignant and benign breast disease.

European journal of cancer (Oxford, England : 1990) - 1 Jan 1990

Pontin J E, Hamed H, Fentiman I S, Idle J R

Abstract excerpt

129 female patients with breast cancer and 79 controls undergoing biopsy for benign breast conditions had debrisoquine hydroxylator phenotype established. 129 female hospital patients with known hydroxylator phenotype were used as another control group. The breast cancer cases differed significantly from the benign controls in their debrisoquine phenotype, with 10% being poor metabolisers compared with none of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Debrisoquin

Share to Genetic Markers

Share to Mixed Function Oxygenases

Share to Phenotype

Source

Identifiers

PMID: 2145896
DOI: 10.1016/0277-5379(90)90153-k

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450dbl phenotypes in malignant and benign breast disease.PMID 2145896Read ↗

Debrisoquine hydroxylase (CYP2D6) and prostate cancer.Semantic proximity Read ↗

Debrisoquine metabolism and lung cancer risk.Semantic proximity Read ↗

The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.Semantic proximity Read ↗

A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.Semantic proximity Read ↗

Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.Semantic proximity Read ↗

Debrisoquin oxidation genotype and susceptibility to lung cancer.Semantic proximity Read ↗

Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.Semantic proximity Read ↗

Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.Semantic proximity Read ↗

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.Semantic proximity Read ↗

Lung tumor resection does not affect debrisoquine metabolism.Semantic proximity Read ↗

New opportunities in cancer risk evaluation using PCR-based DNA analysis for CYP2D6.Semantic proximity Read ↗

Lung cancer and the debrisoquine metabolic phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.